A fatal case of ovarian hyperstimulation syndrome with perforated duodenal ulcer.

Westergaard LG, Yding Andersen C. GnRH agonist (Buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomised study. Hum Reprod 2005; 20:1213–1220. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory hCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006;13:173–178. Humaidan P, Ejdrup Bredkjær, Westergaard L, Yding Andersen C. 1500 IU hCG administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized controlled study. Fertil Steril 2009a Feb 5; [Epub ahead of print] PMID: 19200959. Humaidan P. GnRHa triggering of final oocyte maturation followed by one bolus of 1500 IU hCG rescues the luteal phase and seems to prevent the risk of early onset OHSS in high-risk patients: a prospective proof-of-concept study. Reprod Biomed Online 2009b;18:630–634. Humaidan P, Papanikolaou EG, Tarlatzis BC. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod 2009c;24:2389–2394. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist Fertil Steril 1991;56, 213–220. Kolibianakis EM, Schultze-Mosgau A, Schroer A, Van Steirteghem A, Devroey P, Diedrich K, Griesinger G. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005;20:2887–2892. Tavaniotou A, Devroey P. Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles. Reprod Biomed Online 2006;3:326–330. Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix. Hum Reprod 2001;4:663–667. Youssef M, Griesinger G, Van Wely M, AL-inany H, van der Veen F. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist ART cycles. A systematic review and meta-analysis. Abstracts of the 25th Annual Meeting of ESHRE, Amsterdam, the Netherlands, 28 June 1 July, 2009, p. I115.